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Abstract Leukotriene A4 hydrolase is a cytosolic metalloen-
zyme of the arachidonic acid biosynthetic pathway responsible
for leukotriene A4 conversion into leukotriene B4. In addition to
its epoxide hydrolase properties, this enzyme exhibits an
aminopeptidase activity which was used as an assay to monitor
the purification of a novel form of leukotriene A4 hydrolase from
Xenopus laevis skin exudate. This 70 kDa, secreted, form of
leukotriene A4 hydrolase was identified by immunochemical
cross-reactivity with anti-human leukotriene A4 hydrolase
antibodies and by its capacity to convert leukotriene A4 into
leukotriene B4. Moreover this enzyme produced a second
metabolite which could be the leukotriene B4 isomer 5S,12R-
dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid, previously
shown by Stroºmberg et al. (Eur. J. Biochem. 238 (1996) 599^
605) to be formed by incubation of the leukotriene A4 with
amphibian tissue extracts. Partial amino acid sequencing of
peptides generated by endolysin C fragmentation of the purified
enzyme confirmed the presence, in X. laevis skin secretions, of a
related but distinct form of leukotriene A4 hydrolase which is
likely to be responsible for the production of these eicosanoid
metabolites of leukotriene A4.
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1. Introduction
Leukotrienes belong to a family of eicosanoids derived from
arachidonic acid which biological activity is related to the
in£ammatory response [1]. The biosynthetic pathway leading
to leukotriene A4 (5S-trans-5,6-oxido-7,9-trans-11,14-cis-eico-
satetranoic acid) involves conversion of arachidonic acid by
the 5-lipoxygenase into a labile epoxide, leukotriene A4
(LTA4) which is converted by leukotriene A4 hydrolase into
leukotriene B4 (LTB4 : 5S,12R-dihydroxy-6,14-cis,8,10-trans-
eicosatetranoic acid).
Leukotriene A4 hydrolase is considered as a soluble, cyto-
solic enzyme, which behaves as a 69 kDa monomer. It was
puri¢ed and characterized starting from various cell types and
organisms including guinea pig lung [2] and liver [3], human
lung [4,5], human neutrophils [6] human erythrocytes [7], rat
neutrophils [8] and the Raji, B-lymphocyte cell line [9]. Fur-
thermore, the cDNA clone coding for LTA4 hydrolase was
isolated from human placenta [10], human spleen [11] and rat
mesangial cells [12]. The human LTA4 hydrolase cDNA was
expressed in Escherichia coli [13] and in cultured Spodoptera
frugiperda insect cells [14]. So far LTA4 hydrolase has been
recognized as a Zn2-metalloenzyme [15] and as a bifunctional
hydrolase with intrinsic aminopeptidase activity [16]. More-
over it was recently demonstrated that the amino acid se-
quence of aminopeptidase-B (Ap-B) from the rat testis exhib-
its 33% identity and 48% similarity with leukotriene A4
hydrolase, a relation further supported by the capacity of
Ap-B to hydrolyze in vitro leukotriene A4 [17].
In the course of purifying dactylysin (EC 3.4.24.60) from
Xenopus laevis skin secretions, a Zn2-metalloendopeptidase
with a thermolysin-like selectivity for bulky hydrophobic ami-
no acid side chains [18,19], we have copuri¢ed a protein entity
detected and monitored by mean of its apparent aminopepti-
dase B-like activity. In the present paper we show that this
enzyme exhibits in vitro biochemical properties of a leuko-
triene A4 hydrolase and is structurally related to that enzyme.
2. Materials and methods
2.1. Materials
X. laevis were obtained from the Centre National de la Recherche
Scienti¢que, Montpellier, France. Epinephrine, bovine serum albu-
min, PMSF, GEMSA, bestatin, iodacetamide, orthophenanthroline,
and prostaglandin B1 were purchased from Sigma. Leukotriene A4
methyl ester, leukotriene B4, 6-trans-leukotriene B4 and 6-trans-12-
epi-leukotriene B4 were from Cayman Chemical (Ann Arbor, MI,
USA). Peptides [Arg0,Leu5,Arg6] enkephalin and [Arg0,Leu5] enkeph-
alin were synthesized in our laboratory by the solid-phase method [20]
using a NPS 4000 semi-automated multisynthesizer (Neosystem,
France). Peptide puri¢cation and analysis were routinely conducted
using a set of analytical techniques including HPLC, amino acid
composition, N-terminal sequencing and fast atomic bombardment
mass spectrometry as in [21]. The peptide Arg-Tyr-Gly-Gly-Phe and
Leu5 enkephalin were obtained from Eurogentec (Belgium) and Neo-
system respectively.
2.2. X. laevis skin exudate preparation and enzyme puri¢cation
procedure
Exudate was obtained after dorsal injection of epinephrine (100^200
Wg per animal) and collected by scrapping the frog skin. It was diluted
with about 5 volumes of Tris-HCl 50 mM pH 7.5 and dialyzed ex-
haustively against the same bu¡er for 48 h. The dialyzed material was
subjected to ion exchange chromatography on DEAE Tris-acryl M
(IBF, Villeneuve la Garenne, France) and eluted with 50 mM Tris-
HCl, pH 7.5 bu¡er. This allowed to eliminate more than 90% of the
exudate proteins. The active fractions were recovered in the void
volume, pooled and concentrated to a 15 ml ¢nal volume by using
ultra-free units (Millipore, Saint-Quentin Yvelines, France). Three ml
of the enzymatically active sample was subjected to molecular sieve
¢ltration on a Sephacryl S-100 column (280 ml) equilibrated with 50
mM Tris-HCl, pH 7.5 bu¡er. The active fractions were pooled and
concentrated to be submitted to another molecular sieve ¢ltration on
a Sephadex G-150 (90 ml) column equilibrated with the same bu¡er.
Under such conditions the recovered enzyme activity was found elec-
trophoretically homogeneous on SDS-PAGE. An alternative strategy
used a chromatofocusing step after the DEAE Tris-acryl ion exchange
separation (see above). Polybu¡er exchanger 94 (PBE 94, Pharmacia)
with a pH range 5 to 8 was used. The column (20 ml of PBE 94) was
¢rst equilibrated in 0.025 M Tris-acetic acid pH 8.3. Five ml of the
concentrated active fractions recovered from the DEAE Tris-acryl
step were applied to the column and were eluted with a mixture of
polybu¡er 96 and 74 (30/70; v/v), adjusted to pH 5.0 with acetic acid
to form a pH gradient ranging from 5 to 8. 75 fractions (2 ml) were
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recovered, separately concentrated (¢nal volume 200 Wl) then rinsed
with the Tris-HCl bu¡er (50 mM, pH 7.5) using ultra-free units to
eliminate ampholytes and to assay the enzyme activity. All columns
were run at 4‡C. The partially puri¢ed enzyme was stable for several
months at 4‡C.
2.3. Assay of aminopeptidase activity
Aminopeptidase activity: the enzyme assays were carried out by
incubating 5 Wg of either substrates; i.e. [Arg0,Leu5,Arg6] enkephalin,
[Arg0,Leu5] enkephalin, Arg-Tyr-Gly-Gly-Phe, [Leu5,Arg6] enkepha-
lin or [Leu5] enkephalin with an aliquot of the enzyme preparation in
a 25 Wl ¢nal volume of 50 mM Tris-HCl bu¡er (pH 7.5) during 3 h at
37‡C. The reaction mixture was then applied onto the top of an RP-
HPLC column (Kromasyl C18, 5 Wm, 100 Aî ; 250U4.6 mm from AIT,
Saint Nom la BreteØche, France) and eluted with a linear gradient (10
to 45% acetonitrile in 0.05% TFA) over 18 mn (£ow rate: 1 ml mn31).
The resulting peptide fragments were monitored by UV absorbance at
215 nm and were identi¢ed both by their retention times by reference
to standards and by their amino acid composition. These were per-
formed according to the HPLC Amino Acid Analysis System Pico-
Tag (Waters chromatography division, Milford, MA).
2.4. E¡ects of inhibitors
Aliquots of the enzyme preparation were preincubated with various
inhibitors at the shown concentrations (see Section 3) for 15 min at
37‡C in Tris-HCl bu¡er pH 7.5. The reaction was initiated by addi-
tion of 5 Wg [Arg0,Leu5,Arg6] enkephalin in a 25 Wl ¢nal volume and
carried out for 3 h at 37‡C. Results were compared to those obtained
without inhibitors.
2.5. Assay of leukotriene A4 hydrolase activity
LTA4 methyl ester was ¢rst converted into the free acid by alkaline
hydrolysis according to the manufacturer’s instructions (Cayman
Chemical). Aliquots (30 Wl) of active enzyme preparation were incu-
bated at room temperature with 25 or 50 Wm LTA4 (¢nal volume: 40
Wl). After 30 s, the reaction was stopped by addition of 1 volume of
methanol. The samples were acidi¢ed with acetic acid (5 Wl, 0.1 M)
and were analyzed by reverse-phase HPLC (Kromasyl column C18)
using an isocratic mixture of acetonitrile/methanol/water/acetic acid
(25/40/35/0.01; v/v/v/v). Prostaglandin B1 (PGB1) was used as an
internal standard. The absorbance was monitored at 270 nm.
2.6. Gel electrophoresis
Gel electrophoretic analysis was performed on aliquots of concen-
trated active enzyme fractions under denaturing conditions on 7.5% or
10^15% acrylamide gels using the Phast System (Pharmacia, Uppsala,
Sweden). Proteins were revealed by silver staining.
2.7. Western blot analysis
Protein samples were submitted to 8% SDS-PAGE. Electrotransfer
of proteins to a nitrocellulose membrane (0.45 Wm, Schleicher and
Schuell, Dassel, Germany) was performed with a semi-dry blotting
apparatus (Hoefer). LTA4 hydrolase was detected using polyclonal
anti-human LTA4 hydrolase antibodies (Cayman Chemical; 1/2000
dilution) as described in [17,22].
3. Results
X. laevis skin exudate was used as a source of dactylysin, a
metalloendopeptidase which activity was monitored by HPLC
analysis of peptide fragments generated by selective cleavage
at the Phe-Leu bond of [Arg0,Leu5,Arg6] enkephalin, an hep-
tapeptide best recognized by the enzyme [18]. At each step of
dactylysin puri¢cation it was observed that beside peptide A
(Arg0-Tyr-Gly-Gly-Phe; Fig. 1) i.e. the main product resulting
of dactylysin action on the heptapeptide substrate (S), a sec-
ond product, called peptide B, was formed (Fig. 1). This was
identi¢ed both by its amino acid composition and by its com-
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Fig. 1. HPLC analysis of peptide fragments generated by exposure
of [Arg0,leu5,Arg6] enkephalin (S) to the enzyme active fractions
containing both aminopeptidase and dactylysin activities and recov-
ered at various stages of the puri¢cation procedure (after DEAE Se-
phacryl and Sephacryl S-100 steps). After incubation of 5 Wg (S)
with an aliquot (20 Wl) of enzyme active fraction for 3 h in Tris-
HCl, 50 mM, pH 7.5 at 37‡C, the reaction mixture was applied
onto the top of the HPLC column and was eluted with a gradient
as described in Section 2. A and B were identi¢ed as peptides Arg-
Tyr-Gly-Gly-Phe and Tyr-Gly-Gly-Phe-Leu-Arg respectively. The
pattern here shown is an example of the routine analysis on incom-
pletely separated form of the two enzyme activities.
Fig. 2. A: Separation of datylysin (a) and aminopeptidase B-like
(b) activities by molecular sieve ¢ltration on a Sephadex G-150 col-
umn in Tris-HCl, 50 mM, pH 7.5. The activities expressed as arbi-
trary units were monitored on 20 Wl aliquots of each 1 ml recovered
fraction as described in Section 2 using (S: Arg-Tyr-Gly-Gly-Phe-
Leu-Arg) as substrate (see legend to Fig. 1). A280nm (T). B: SDS-
PAGE electrophoresis on the Phast System on polyacrylamide 7.5%
gels. Each of the analyzed 1 ml fraction was concentrated to about
50 Wl ¢nal volume and a 4 Wl aliquot was submitted to electrophore-
sis. Lanes 1, 2 and 3 correspond to fractions 42, 44 and 46 respec-
tively from molecular sieve ¢ltration of A. Lane M: molecular mass
markers in kDa. C: HPLC test of aminopeptidase B-like activity
(arbitrary units) on fraction 46 (see A and Fig. 3A, lane 3). Details
in Section 2 and legend to Fig. 1. S, Arg-Tyr-Gly-Gly-Phe-Leu-Arg;
B, Tyr-Gly-Gly-Phe-Leu-Arg.
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parison with standard peptides, as representing Tyr-Gly-Gly-
Phe-Leu-Arg and was assumed to result from the action of an
aminopeptidase B-like activity on the peptide substrate. In-
deed both dactylysin and aminopeptidase activities were not
separated at the DEAE-Sephadex step and were coeluted to-
gether with the unadsorbed proteins (not shown); the latter
represented roughly 10% of the total applied onto the top of
the column. Whereas the two activities could not be entirely
separated by exclusion chromatography on Sephacryl S-100
(not shown), molecular sieve ¢ltration on Sephadex G-150
clearly achieved a signi¢cant separation (Fig. 2A). After pool-
ing and concentration of the relevant G-150 fractions contain-
ing the aminopeptidase activity, SDS-PAGE analysis of the
corresponding protein indicated that this enzyme reaction was
performed by a 70 kDa protein entity (Fig. 2B, lane 3 and
Fig. 2C).
Puri¢cation of the aminopeptidase activity by chromatofo-
cusing revealed a microheterogeneity with species of respective
apparent pI 6.3, 6.5, 6.7, 6.9 (Fig. 3A). The latter was found
to be free of endopeptidase activity and of any contaminant
on SDS-PAGE using the Phast System (70 kDa band on Fig.
3B, C). This 70 kDa species exhibited, together with an ami-
nopeptidase B-like activity toward [Arg0,Leu5] enkephalin and
Arg-Tyr-Gly-Gly-Phe which were transformed in [Leu5] enke-
phalin and Tyr-Gly-Gly-Phe respectively, a weaker but broad-
er aminopeptidase activity. This was shown on such peptides
as [Leu5,Arg6] enkephalin and [Leu5] enkephalin, both sub-
strates from which the N-terminal tyrosine residue was elim-
inated (summarized in Table 1) by leukotriene A4 hydrolase
as previously described by Gri⁄n et al. [23] and Nissen et al.
[24].
The enzyme was not inhibited by either PMSF (1 mM),
GEMSA (250 WM), and iodacetamide (1 mM); it is neither
serine nor thiol protease. Its activity was abolished by either
bestatin (0.2 mM) or orthophenanthroline (1 mM) con¢rming
both its amino- and metallopeptidase character.
Western blot analysis indicated that whereas the 70 kDa
species was not recognized by the aminopeptidase-B antibod-
ies (not shown), a strong reaction was obtained by using anti-
human LTA4 hydrolase antibodies (Fig. 4).
Final demonstration that the 70 kDa species with exopep-
tidase activity was indeed LTA4 hydrolase was achieved:
FEBS 20647 14-8-98
Fig. 3. A: Chromactofocusing analysis of aminopeptidase B-like activity. Elution pro¢le observed by measurement of aminopeptidase B-like ac-
tivity (a : arbitrary units) as described in details in Section 2 on 2 ml fractions. A280nm (9) and pH (R). B: SDS-PAGE (10^15%) on the Phast
System. Lanes 1, 2 and 3 represent 4 Wl aliquots of previously concentrated fractions 55 (220 Wl), 56 (215 Wl) and 57 (165 Wl) respectively. Lane
M: molecular mass markers in kDa. C: HPLC test of aminopeptidase B-like activity (arbitrary units) on fraction 56 (see A and B, lane 2) De-
tails in Section 2 and Fig. 1. S, Arg-Tyr-Gly-Gly-Phe-Leu-Arg; B, Tyr-Gly-Gly-Phe-Leu-Arg.
Table 1
Representation of major (S), and minor (S and s) cleavages pro-
duced by aminopeptidase B-like activity of X. laevis skin secretion
LTA4 hydrolase in a series of enkephalin-related peptides
Fig. 4. Western blot analysis of aminopeptidase B-like activity. The
enzyme active fractions recovered after Sephacryl S-100 chromatog-
raphy (see Section 2) were run on 8% SDS-PAGE and analyzed by
immunochemical blotting using polyclonal anti-human LTA4 hydro-
lase antibodies (1/2000 dilution). Lanes 1, 2 and 3 represent same
sample at three di¡erent concentrations (1, 3 and 7).
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(i) by showing its capacity to convert LTA4 into LTB4 (Fig. 5)
and (ii) by determining the amino acid sequence of three pep-
tides obtained by endolysin C fragmentation of the pure pro-
tein. The microsequencing of octapeptide, hexapeptide and
undecapeptide fragments indicated respectively 87.5%, 100%
and 36% sequence similarity and respectively 62.5%, 100%
and 21% sequence identity with the corresponding reference
peptides from human LTA4 hydrolase sequence (not shown;
[10]). Noticeably the LTA4 hydrolase activity was clearly de-
tected at all stages of puri¢cation, i.e. after the DEAE Seph-
acryl, Sephacryl S-100 and Sephadex G-150 chromatography
and chromatofocusing steps (not shown). Finally a secondary
product was observed in the HPLC analysis of the products of
LTA4 conversion into LTB4 (marked V on Fig. 5). In the
di¡erent studied extracts, this compound appeared in a fairly
constant ratio relative to LTB4 (not shown) as observed by
Stroºmberg et al. [25]. This observation strongly suggested that
this could represent compound X (5S,12-dihydroxy-6,10-
trans-8,14-cis-eicosatetranoic acid) previously detected [25] in
frog tissue extracts.
4. Discussion
Previous work from [25] has suggested the presence of
LTA4 hydrolase in X. laevis on the basis of the detection of
LTB4 in the nine amphibian organs tested. Additionally in-
cubations of supernatants of these organ homogenates with
LTA4 revealed the formation of the unexpected compound X
which was shown to be 5S,12R-dihydroxy-6,10-trans-8,14-cis-
eicosatetraenoic acid. The authors concluded that this com-
pound was resulting from an activity associated, indirectly or
directly, to leukotriene A4 hydrolase.
In the present report we have demonstrated unequivocally
that X. laevis skin exudate contains an enzyme activity capa-
ble to hydrolyze LTA4 into LTB4 and also to convert part of
substrate into a compound, probably corresponding to com-
ponent X described by Stroºmberg et al. ; both products were
formed in vitro by the same puri¢ed LTA4 hydrolase.
Site-directed mutagenesis observations on human recombi-
nant LTA4 hydrolase at a key residue of the catalytic site, i.e.
mutations Tyr 378 F and Tyr 378 Q, both generated a mu-
tated form of the enzyme capable to produce in vitro com-
pound X [26]. Partial sequencing of endolysin C peptide frag-
ments of the presently described LTA4 hydrolase has shown a
high degree of sequence similarity in two domains (87.5 and
100%) but clear discrepancies on another peptide of the hu-
man LTA4 hydrolase reference enzyme. These observations
suggest that the X. laevis LTA4 hydrolase might be a closely
related enzyme but possessing selective amino acid modi¢ca-
tions which could account for the capacity of this amphibian
enzyme to produce the component X. Determination of the
complete sequence of the cloned enzyme cDNA should clarify
this issue and help establishing the molecular basis for this
catalytic di¡erence and particularly verify whether the protein
has an intrinsic mutation in the Tyr 378 position. Interestingly
Tyr 378 is replaced by a phenylalanine in the primary se-
quence of a protein from Dictyostelium discoideum, presumed
to be a LTA4 hydrolase (accession number: V27538; Iho and
Kopachik, 1995, unpublished data; [17]).
Another interesting point deals with the presence of X.
Laevis LTA4 hydrolase in skin secretions. Although exudation
process di¡ers from classical exocytose since the secretory
granules conserved their membranes after expulsion, it could
be hypothesized that the LTA4 hydrolase described in this
paper possesses structural properties allowing for its secretion.
Noticeably although LTA4 hydrolase was established as a
cytosolic enzyme, its presence was reported in human plasma
extracts [27].
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